Secondary hypocortisolism is a condition defined by insufficient cortisol production by the adrenal cortex due to a deficiency of adrenocorticotropic hormone (ACTH), produced by the pituitary gland. Secondary adrenal insufficiency is therefore one of the manifestations of hypopituitarism, a condition characterized by one or more hormonal deficiencies resulting from partial or total loss of pituitary gland function. The various hormonal deficiencies that may arise in hypopituitarism produce a clinical picture that is vague and nonspecific, yet potentially fatal, rendering diagnosis complex. Nevertheless, suboptimal management of pituitary deficiencies constitutes a risk factor for the development of cardiovascular and metabolic comorbidities, considerably worsening patients' quality of life and increasing their mortality. Among the various complications that may emerge, the most fearsome is acute adrenal insufficiency, or adrenal crisis, a medical emergency that can prove fatal if not promptly recognized and diagnosed. The primary aim of this retrospective observational study is to explore the incidence of metabolic, skeletal, and cardiovascular comorbidities, as well as to assess the impact of complications such as infectious events and adrenal crises on mortality in patients with secondary hypocortisolism. As a secondary objective, the effectiveness of treatment in patients affected by this condition at the Padua University Hospital (AOPD) was evaluated and compared with other centers. A total of 201 patients referred to the Padua University Hospital (AOPD) between July 2008 and July 2026 were enrolled. Data were collected regarding the onset and severity of hypopituitarism, treatment administered, replacement corticosteroid therapy, comorbidities, and complications such as infectious events, adrenal crises, and, where applicable, death. The results showed that a greater number of deficiencies is associated with the development of a greater number of comorbidities, specifically demonstrating that hypogonadism and growth hormone deficiency (GHD) predispose to peripheral arterial disease, while hypothyroidism predisposes to dyslipidemia. The protective role of recombinant growth hormone (rGH) therapy in preventing hypertension in patients with GHD was also confirmed (p = 0,001). Furthermore, patients with a greater number of deficiencies were treated with higher equivalent doses of hydrocortisone. No significant results emerged regarding improved management of hypocortisolism based on the formulation of steroid therapy used. However, the risks of steroid replacement therapy overdosing were highlighted, being associated with increased mortality (p = 0,010) and a higher prevalence of hepatic steatosis (p = 0,037) and cerebrovascular disease. Patients at greatest risk of developing adrenal crises were those with older age (p = 0,031), older age at diagnosis (p = 0,031), combined pituitary hormone deficiency (p = 0.037), and the presence of multiple comorbidities, particularly cardiovascular disease, hypertension (p = 0,037), or dyslipidemia. Gastrointestinal tract infections, lower respiratory tract infections, and healthcare-associated infections proved to be triggering factors for adrenal crises, in addition to being associated with increased mortality. A higher number of adrenal crises (p = 0,023) and, marginally, treatment with at least one cycle of radiotherapy (p = 0,073) were factors associated with increased mortality. The incidence rate of adrenal crises in this cohort was 6,08 crises per person-year, nearly double that reported by other centers. Despite the limitations of this study related to its retrospective observational design and the limited cohort size, the significant findings and emerging trends warrant further investigation in future analyses to improve the quality of life and management of secondary hypocortisolism.
L’ipocorticismo secondario è una patologia definita come l’insufficiente produzione di cortisolo da parte della corteccia delle ghiandole surrenaliche in seguito ad una carenza di ormone adrenocorticotropo (ACTH), prodotto dall’ipofisi. L’iposurrenalismo secondario è quindi una delle manifestazioni dell’ipopituitarismo, una condizione caratterizzata da uno o più deficit ormonali dovuti alla perdita di funzione parziale o totale dell’ipofisi. I vari deficit ormonali propri dell’ipopituitarismo causano un quadro clinico aspecifico ma potenzialmente mortale, che ne complica la diagnosi. Tuttavia, il trattamento non ottimale dei deficit ipofisari è un fattore di rischio per lo sviluppo di comorbidità cardiovascolari e metaboliche, peggiorando la qualità di vita del paziente e aumentandone la mortalità. Tra le possibili complicanze la più temibile è l’insufficienza surrenalica acuta, un’emergenza medica che può risultare fatale se non riconosciuta e diagnosticata tempestivamente. Lo scopo primario di questo studio osservazionale retrospettivo è l’esplorazione dell’incidenza di comorbidità metaboliche, ossee, e cardiovascolari, oltre alla valutazione delle complicanze quali eventi infettivi e crisi surrenaliche sulla mortalità del paziente con ipocorticismo secondario. Secondariamente, è stata valutata l’efficacia del trattamento dei pazienti affetti da tale patologia presso l’Azienda Ospedale-Università di Padova (AOPD) confrontandola con gli altri centri. Sono stati reclutati 201 pazienti afferenti presso l’AOPD nel periodo temporale esteso dal luglio 2008 al luglio 2026 raccogliendone i dati riguardanti: insorgenza ed entità dell’ipopituitarismo; trattamento eseguito; terapia cortisonica sostitutiva; comorbidità presenti e complicanze come gli eventi infettivi, le crisi surrenaliche ed eventualmente il decesso. I risultati emersi hanno evidenziato come un numero maggiore di deficit porti a sviluppare un numero maggiore di comorbidità, mostrando specificamente come l’ipogonadismo e il GHD predispongano allo sviluppo di arteriopatia periferica e l’ipotiroidismo predisponga alla dislipidemia. È stato inoltre confermato il ruolo protettivo della terapia con rGH nella prevenzione dell’ipertensione nei pazienti con GHD (p=0,001). Inoltre, i pazienti con un numero maggiore di deficit sono trattati con un dosaggio equivalente di idrocortisone maggiore. Non sono emersi risultati significativi su una migliore gestione dell’ipocorticismo in base alla formulazione della terapia steroidea utilizzata. Sono stati tuttavia evidenziati i rischi di un sovradosaggio della terapia steroidea sostitutiva, associata ad una maggiore mortalità (p=0,010) e alla maggior prevalenza di steatosi (p=0,037) e patologie cerebrovascolari. I pazienti maggiormente a rischio di sviluppare crisi surrenaliche sono quelli con un’età elevata (p=0,031), un’età avanzata alla diagnosi (p=0,031), un deficit ipofisario combinato (p=0,037) e la presenza di più comorbidità, in particolare affetti da patologie cardiovascolari, ipertensione o dislipidemia. Le infezioni del tratto gastroenterico, delle basse vie aeree e le infezioni correlate all’assistenza si sono dimostrate dei fattori scatenanti per le crisi surrenaliche, oltre ad essere associate ad un aumento della mortalità. Un maggior numero di crisi surrenaliche (p=0,023) e marginalmente il trattamento con almeno un ciclo di radioterapia (p=0,073) sono fattori che comportano un aumento della mortalità. Il tasso di incidenza di crisi surrenaliche nella casistica è pari a 6,08 crisi per persona-anno, quasi il doppio rispetto a quanto riportato in altri centri. Nonostante i limiti di questo studio legati alla sua struttura osservazionale retrospettiva e la ridotta numerosità della coorte, i risultati emersi sono degni di essere esplorati in analisi successive per migliorare la qualità di vita e la gestione dell’ipocorticismo secondario.
Morbidità e mortalità in una coorte monocentrica di pazienti con insufficienza surrenalica secondaria con follow up superiore a 10 anni.
NIERO, ARES
2025/2026
Abstract
Secondary hypocortisolism is a condition defined by insufficient cortisol production by the adrenal cortex due to a deficiency of adrenocorticotropic hormone (ACTH), produced by the pituitary gland. Secondary adrenal insufficiency is therefore one of the manifestations of hypopituitarism, a condition characterized by one or more hormonal deficiencies resulting from partial or total loss of pituitary gland function. The various hormonal deficiencies that may arise in hypopituitarism produce a clinical picture that is vague and nonspecific, yet potentially fatal, rendering diagnosis complex. Nevertheless, suboptimal management of pituitary deficiencies constitutes a risk factor for the development of cardiovascular and metabolic comorbidities, considerably worsening patients' quality of life and increasing their mortality. Among the various complications that may emerge, the most fearsome is acute adrenal insufficiency, or adrenal crisis, a medical emergency that can prove fatal if not promptly recognized and diagnosed. The primary aim of this retrospective observational study is to explore the incidence of metabolic, skeletal, and cardiovascular comorbidities, as well as to assess the impact of complications such as infectious events and adrenal crises on mortality in patients with secondary hypocortisolism. As a secondary objective, the effectiveness of treatment in patients affected by this condition at the Padua University Hospital (AOPD) was evaluated and compared with other centers. A total of 201 patients referred to the Padua University Hospital (AOPD) between July 2008 and July 2026 were enrolled. Data were collected regarding the onset and severity of hypopituitarism, treatment administered, replacement corticosteroid therapy, comorbidities, and complications such as infectious events, adrenal crises, and, where applicable, death. The results showed that a greater number of deficiencies is associated with the development of a greater number of comorbidities, specifically demonstrating that hypogonadism and growth hormone deficiency (GHD) predispose to peripheral arterial disease, while hypothyroidism predisposes to dyslipidemia. The protective role of recombinant growth hormone (rGH) therapy in preventing hypertension in patients with GHD was also confirmed (p = 0,001). Furthermore, patients with a greater number of deficiencies were treated with higher equivalent doses of hydrocortisone. No significant results emerged regarding improved management of hypocortisolism based on the formulation of steroid therapy used. However, the risks of steroid replacement therapy overdosing were highlighted, being associated with increased mortality (p = 0,010) and a higher prevalence of hepatic steatosis (p = 0,037) and cerebrovascular disease. Patients at greatest risk of developing adrenal crises were those with older age (p = 0,031), older age at diagnosis (p = 0,031), combined pituitary hormone deficiency (p = 0.037), and the presence of multiple comorbidities, particularly cardiovascular disease, hypertension (p = 0,037), or dyslipidemia. Gastrointestinal tract infections, lower respiratory tract infections, and healthcare-associated infections proved to be triggering factors for adrenal crises, in addition to being associated with increased mortality. A higher number of adrenal crises (p = 0,023) and, marginally, treatment with at least one cycle of radiotherapy (p = 0,073) were factors associated with increased mortality. The incidence rate of adrenal crises in this cohort was 6,08 crises per person-year, nearly double that reported by other centers. Despite the limitations of this study related to its retrospective observational design and the limited cohort size, the significant findings and emerging trends warrant further investigation in future analyses to improve the quality of life and management of secondary hypocortisolism.| File | Dimensione | Formato | |
|---|---|---|---|
|
Niero_Ares.pdf
accesso aperto
Dimensione
1.54 MB
Formato
Adobe PDF
|
1.54 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/116698